Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H22ClN7 |
| Molecular Weight | 407.899 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CN(CCN1)C2=CC=C3N=C(NC4=C(C)C=CC=C4Cl)C5=CN=CN5C3=N2
InChI
InChIKey=PUNYTBZWCMNSRO-AWEZNQCLSA-N
InChI=1S/C21H22ClN7/c1-13-4-3-5-15(22)19(13)27-20-17-10-23-12-29(17)21-16(25-20)6-7-18(26-21)28-9-8-24-14(2)11-28/h3-7,10,12,14,24H,8-9,11H2,1-2H3,(H,25,27)/t14-/m0/s1
| Molecular Formula | C21H22ClN7 |
| Molecular Weight | 407.899 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. | 2004 Aug 26 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:27:37 GMT 2023
by
admin
on
Sat Dec 16 09:27:37 GMT 2023
|
| Record UNII |
8FX9DP2Y1W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8FX9DP2Y1W
Created by
admin on Sat Dec 16 09:27:37 GMT 2023 , Edited by admin on Sat Dec 16 09:27:37 GMT 2023
|
PRIMARY | |||
|
9844320
Created by
admin on Sat Dec 16 09:27:37 GMT 2023 , Edited by admin on Sat Dec 16 09:27:37 GMT 2023
|
PRIMARY | |||
|
240814-54-4
Created by
admin on Sat Dec 16 09:27:37 GMT 2023 , Edited by admin on Sat Dec 16 09:27:37 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
